Hypersensitivity Clinical Trial
— SHInEOfficial title:
Effects of Interventions to Prevent Work-related Asthma, Allergy and Other Hypersensitivity Reactions in Norwegian Salmon Industry Workers (SHInE)
Verified date | November 2022 |
Source | University Hospital of North Norway |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Workers in the salmon industry are at risk of developing allergies and respiratory diseases, including asthma, due to occupational exposure to bioaerosols, i.e. biological agents such as allergens, enzymes and endotoxins, in their work environment. The overall objective of this intervention trial is to identify effective and feasible control measures (interventions) that reduce exposure to these bioaerosols. The project comprises nine salmon processing factories in northern, central and western Norway. The factories are allocated to either one of the two intervention arms or the control group. In all factories, an assessment of exposure to bioaerosols will be performed. In addition, employees will be invited to undergo a health examination and fill out a self-administered questionnaire including information on demographics, work tasks, health and health promoting factors. The intervention trial is part of a broader study that comprises several substudies including the identification of clinically relevant allergens, investigation of exposure-response relationship between the exposure to individual bioactive agents in bioaerosols and investigations of prevalence of airway symptoms, altered lung function, skin symptoms or immunological responses indicating hypersensitivity. Finally the project includes the identification of health promoting factors that are present in the salmon processing industry. The project is an interdisciplinary multi-center study that places great emphasis on a close dialogue between the researchers and industry in all phases of the project.
Status | Enrolling by invitation |
Enrollment | 2000 |
Est. completion date | April 30, 2025 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Eligibility criteria will differ depending on the type of data gathering volunteers participate in: 1. Questionnaire Inclusion Criteria: All workers employed in the factory Exclusion Criteria: No restrictions 2. Exposure assessment study Inclusion Criteria: Participants (12 workers each day, two repeated measurements = 24 workers) will be collected at random among workers having the following work stations/tasks during the study period: Monday and Thursday (n=12 workers): Slaughtering department (n=5), filleting department (n=4) and other (n=3). Tuesday and Wednesday (n=12 workers): Slaughtering department (n=3), filleting department (n=3), packing department (n=2), laboratory/technical department (n=2) and central control room/administration (n=2). Exclusion Criteria: Not working in those areas, not able to wear backpack with equipment. 3. Cross-week follow-up (Monday to Thursday) Inclusion Criteria: Participant in both 1 and 2, i.e. having filled out questionnaire and participated in exposure measurement on mondays. Exclusion Criteria: Not fulfilling inclusion criteria, not able to wear backpack with equipment. 4. Health examinations Inclusion criteria: All subjects working in the factories during the field work period of four days will be eligible. However, due to logistic constraints we aim to invite at least 20 subjects each day, primarily those working in the salmon production line. Those invited will be randomly selected according to a distribution between slaughtering, filleting and others (ratio 5:4:3). Exclusion criteria: - For spirometry measurements: heart attack, operation on eyes, stomach or in the chest region in the course of the last three months, ongoing treatment for tuberculosis or other respiratory infection, pregnancy - For skin prick tests: pregnancy |
Country | Name | City | State |
---|---|---|---|
Norway | University Hospital of Nothern Norway | Tromsø |
Lead Sponsor | Collaborator |
---|---|
University Hospital of North Norway | Haukeland University Hospital, St. Olavs Hospital, The Research Council of Norway, UiT The Arctic University of Norway, University of Bergen |
Norway,
Hoper AC, Kirkeleit J, Thomassen MR, Irgens-Hansen K, Hollund BE, Fagernaes CF, Svedahl SR, Eriksen TE, Grgic M, Bang BE. Effects of Interventions to Prevent Work-Related Asthma, Allergy, and Other Hypersensitivity Reactions in Norwegian Salmon Industry Workers (SHInE): Protocol for a Pragmatic Allocated Intervention Trial and Related Substudies. JMIR Res Protoc. 2023 Jul 19;12:e48790. doi: 10.2196/48790. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of salmon processing workers' personal exposure to inhalable protein | Change in inhalable total protein (ug/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change of salmon processing workers' personal exposure to proteases | Change in concentration of proteases (ng/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change in area concentration of airborne total protein (stationary measurements) | Change in total protein (ug/m3, inhalable aerosol fraction) from stationary measurements in relevant areas of the salmon production line from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change of salmon processing workers' personal exposure to airborne fish allergens | Change in concentration of total aerosol fraction of fish allergens (ng/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change of salmon processing workers' personal exposure to airborne endotoxins | Change in mean concentration of inhalable total endotoxin units (EU/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' self-reported symptoms from the upper airways | Since the investigators expect to have a significant "loss to follow-up" from T1 to T2,the investigators will analyze change in prevalence of self-reported symptoms from the nose from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of symptoms from the respiratory system will be assessed using information reported by participants through a questionnaire that includes standardized questions on respiratory symptoms (upper and lower airways), allergic status and malaise (European Community Respiratory Health Survey, ECRHS). Differences between intervention groups and between intervention groups and control group will be analyzed. | Data collected at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' self-reported symptoms from the lower airways | Since the investigators expect to have a significant "loss to follow-up" from T1 to T2, the investigators will analyze change in prevalence of self-reported symptoms from the chest from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of symptoms from the respiratory system, as well as the asthma symptom score (0-5) will be assessed using information reported by participants through a questionnaire that includes standardized questions on respiratory symptoms (upper and lower airways), allergic status and malaise (European Community Respiratory Health Survey, ECRHS). Differences between intervention groups and between intervention groups and control group will be analyzed. | Data collected at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' self-reported eye symptoms | Since the investigators expect to have a significant "loss to follow-up" from T1 to T2, the investigators will analyze change in prevalence of self-reported symptoms from the eye pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of eye symptoms will be assessed using information reported by participants through the a set of standardized questions in a questionnaire.Differences between intervention groups and between intervention groups and control group will be analyzed. | Data collected at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' lung function at group level (FEV1 in % of predicted) | Change in proportion of participants having a decline in maximum forced expired volume in 1 second (FEV1 in % of predicted), from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' lung function at individual level (maximum forced expired volume in 1 second (FEV1)/forced vital capacity (FVC) ratio) | Mean of individual change in maximum forced expired volume in 1 second (FEV1) in % of forced vital capacity (FEV1/FVC ratio), from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) for individuals, provided low loss-to follow up. Differences between intervention groups and between intervention groups and control group will be analyzed. | Data collected at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' cross-shift lung function (FEV1) | Change in mean difference between pre-shift values and post-shift values (cross-shift) in maximum forced expired volume in 1 second (FEV1, in liter and % of predicted) of individual salmon processing workers from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) .Differences between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' cross-week lung function (FEV1) | Change in mean difference between pre-shift values on Monday and post-shift values on Thursday (cross-week) in maximum forced expired volume in 1 second (FEV1, in liter and % of predicted) of individual salmon processing workers from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) .Differences between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Incidence of salmon processing workers' sensitization to salmon | Registration of number of salmon workers that are newly sensitized to salmon at follow-up. Sensitization will be assessed by serum immunoglobulin E (IgE) specific to salmon proteins. Individuals that are negative for specific immunoglobulin E (IgE) at pre-intervention (baseline, T1) and positive at post-intervention (follow-up (T2) will be registered as an incidence case. Differences between intervention groups and between intervention groups and control group will be analyzed. | Measurements at T1 compared to T2, 12 months after T1. | |
Secondary | Change in salmon processing workers' self-reported skin symptoms | Since the investigators expect to have a significant "loss to follow-up" from T1 to T2, the investigators will analyze change in prevalence of self-reported skin symptoms from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Skin symptoms will be assessed using information from a questionnaire that includes standardized questions on eczema, other symptoms from the skin and urticaria (Nordic Occupational Skin Questionnaire, The Nordic Occupational Skin Questionnaire NOSQ-2002). Differences between intervention groups and between intervention groups and control group will be analyzed. | Data collected at T1 compared to T2, 12 months after T1. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531540 -
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
|
Phase 3 | |
Completed |
NCT00988065 -
Sugammadex Hypersensitivity Study (Study P06042)
|
Phase 1 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02588326 -
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
|
Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Completed |
NCT01494649 -
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
|
N/A | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Completed |
NCT04006106 -
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
|
||
Completed |
NCT04605471 -
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Terminated |
NCT05247567 -
Quaternary Ammonium and Immunization in Hairdressers
|
N/A | |
Completed |
NCT05119751 -
Vestibular Versus Sublingual Route of AIT Tablets
|
Phase 4 | |
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Not yet recruiting |
NCT04485299 -
Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient
|
Phase 2/Phase 3 | |
Completed |
NCT02686827 -
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
|
Phase 2 | |
Completed |
NCT00850668 -
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
|
Phase 1 |